This article is more than 5 years old. Information may no longer be current.

Stryker receives FDA clearance for VertaPlex HV in treatment of sacral insufficiency fractures

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Stryker Corporation recently announced its Interventional Spine business unit received FDA clearance to market its expanded indications of VertaPlex HV for the treatment of sacral insufficiency fractures.

According to a company press release, VertaPlex HV is the first polymethylmethacrylate (PMMA) to receive 510(k) clearance for the fixation of pathological fractures of the sacral vertebral body or ala using sacral vertebroplasty or sacroplasty.

“Careful intraoperative technique and VertaPlex HV PMMA is an excellent and safe solution in the management of sacral fractures,” Jeffrey W. Miller, MD, principal investigator of the Stryker-sponsored study for the 510(k) submission, stated in the press release.

Reference: www.stryker.com.